20 April 2022

To: Recipients of M59, 3rd ed.

From: Jennifer K. Adams, MT(ASCP), MSHA
Vice President, Standards and Quality

Subject: Correction

This notice is intended to inform users of a correction made to CLSI document M59, *Epidemiological Cutoff Values for Antifungal Susceptibility Testing*, 3rd ed. The correction is described below and shown as stricken/highlighted text in the table excerpt.

Table 6. Summary of Available Epidemiological Cutoff Values and/or Breakpoints by Fungal Species

The voriconazole listing for *Candida glabrata* is listed incorrectly as having a breakpoint (BP). The listing has been corrected to read “ECV” alone for accuracy.

Table 6. Summary of Available Epidemiological Cutoff Values and/or Breakpoints by Fungal Species

<table>
<thead>
<tr>
<th>Species</th>
<th>Drugs</th>
<th>Amphotericin B</th>
<th>Anidulafungin</th>
<th>Caspofungin</th>
<th>Fluconazole</th>
<th>Flucytosine</th>
<th>Isavuconazole</th>
<th>Itraconazole</th>
<th>Micafungin</th>
<th>Posaconazole</th>
<th>Voriconazole</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>Candida glabrata</em></td>
<td>ECV</td>
<td>BP/ECV</td>
<td>BP</td>
<td>BP</td>
<td>BP</td>
<td>BP</td>
<td>-</td>
<td>-</td>
<td>BP</td>
<td>ECV</td>
<td>BP/ECV</td>
</tr>
</tbody>
</table>

If you require any additional clarification regarding these corrections, please contact CLSI Customer Service ([customerservice@clsi.org](mailto:customerservice@clsi.org)).

We appreciate your commitment to CLSI and regret any inconvenience.